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Lanthanum kinetics  
in renal failure
Although lanthanum carbonate, a new 
phosphate binder, is poorly absorbed 
from the gastrointestinal tract, its rate of 
absorption is increased during renal fail-
ure. As they report in this issue, Bervoets 
et al. studied the kinetics of its distribution 
using many state-of-the-art methods. They 
found that lanthanum was primarily stored 
in liver lysosomes, and that animals with 
renal failure had higher levels of lanthanum 
in the liver, largely reflecting increased 
absorption. Interestingly, increased lantha-
num was also found in the biliary canals, 
suggesting this location as its normal mode 
of exit from the body. When rats with renal 
failure were fed lanthanum orally, levels 
doubled in the liver while serum lantha-
num levels remained the same. However, 
when lanthanum was administered intra-
venously, its levels in the liver were the 
same in normal and uremic animals. These 
studies suggest that lanthanum is normally 
absorbed in the intestine and stored in 
lysosomes, then excreted into the bile. 
The mechanism of increased lanthanum 
absorption in the intestine remains to be 
identified. See page 389.
Kidney disease  
in the age of HAART
Treatment of AIDS with highly active anti-
retroviral therapy (HAART) has prolonged 
lives and reduced morbidity, thus converting 
the disease from one that was uniformly and 
rapidly fatal to one that is now close to being 
a ‘chronic’ disease with prolonged survival. 
Immediately after the original descriptions 
of AIDS, it became clear that the disease was 
associated with rapidly progressive glomer-
ulosclerosis. Wyatt et al. now provide renal 
pathology in a group of patients with AIDS 
treated with antiretroviral therapy who con-
sented to donate their organs before death. A 
form of renal pathology was found in most 
patients, while only one-third of the patients 
had CKD at the time of death. The lesions 
included HIV-associated nephropathy, arte-
riolar nephrosclerosis, and glomerulonephri-
tis. It was possible to find microalbuminuria 
in these stored specimens. These studies sug-
gest that CKD is very prevalent in patients 
undergoing treatment for AIDS. The wide 
spectrum of kidney disease found by the 
authors suggests that clinicians should screen 
early for a diagnosis of AIDS, and for kid-
ney disease in patients with AIDS. Earlier 
identification of AIDS could lead to earlier 
treatment with antiretroviral therapy, which 
may delay the progression of AIDS and its 
associated kidney diseases. See page 428. 
ANP and adreno­
medullin in CKD
A-type natriuretic peptide (ANP) and 
adrenomedullin are known vasodilators 
and natriuretic factors. ANP was first iden-
tified as being produced in the heart but 
is also synthesized by the kidney tubule. 
Similarly, adrenomedullin, first isolated 
from pheochromocytoma, is also synthe-
sized by the kidney. However, it is not clear 
what amount of these peptides’ circulating 
levels is derived from or metabolized by the 
kidney. Dieplinger et al. present a study in 
which they measured the plasma concen-
trations of the prohormones of these fac-
tors in patients with chronic kidney disease 
(CKD) to determine whether they are pre-
dictive of renal failure. Using a database of 
177 patients with CKD who were followed 
for 7 years, the authors found an excellent 
correlation between the levels and glomer-
ular filtration rate (GFR) measurements. 
Further, they found that the levels were 
strong predictors of progression of renal 
failure, even after adjustment for GFR and 
proteinuria. This research cannot prove 
whether these peptides accumulate when-
ever renal failure progresses, because the 
accumulation reflects reduced renal mass 
for synthesis. Yet ANP and adrenomedul-
lin are excellent markers for disease pro-
gression. In addition, these studies might 
provide a useful surrogate marker for 
progression of renal disease given the con-
tinuing confusion regarding which method 
most accurately reflects the real GFR in 
patients with CKD. See page 408. 
It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
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